How to Search Drug Patents: The Competitive Intelligence Skill Pharma Executives Can’t Afford to Skip
There is a certain type of pharmaceutical executive who still thinks of patent searching as something lawyers do—a back-office function […]
Generic Drug Approval: The Complete Pharma Playbook (FDA, EMA, Patents, IP Valuation)
Generic drug approval is, at its core, a race with rules. The company that reads the rules fastest and most
Generic Drug Approval: The Complete Pharma Playbook (FDA, EMA, Patents, IP Valuation) Read Post »
Strategies for Successful Biosimilar-to-Biosimilar Switching: Navigating Clinical, Regulatory, and Market Complexities
Biosimilar-to-Biosimilar Switching: The Complete IP, Clinical, and Market Playbook For pharma IP teams, portfolio managers, R&D leads, and institutional investors
What Triggers a Paragraph IV Filing: The Definitive Analyst’s Guide to Drug Patent Challenge Predictors
The 55% figure should stop every pharma IP team in its tracks. That is the share of new small-molecule drugs
Generic Drug Partnerships: The Definitive IP and Deal Structure Playbook for ANDA Filers
Generic drug development has never been a solo endeavor, but the industry has spent the last decade pretending otherwise. Companies
Generic Drug Partnerships: The Definitive IP and Deal Structure Playbook for ANDA Filers Read Post »
Generic Drug Development Timelines: The Definitive Playbook for Faster ANDA Approval
The average generic drug program takes 3 to 4 years from target identification to FDA approval. For most companies, that
Generic Drug Development Timelines: The Definitive Playbook for Faster ANDA Approval Read Post »
Using Drug Patents to Block Competitors: The Tactics and Consequences
Strategic Patent Barriers and Market Exclusivity in the Pharmaceutical Industry Pharmaceutical companies use patent portfolios to prevent generic and biosimilar
Using Drug Patents to Block Competitors: The Tactics and Consequences Read Post »
Fix Your Generic Drug Supply Chain Before a Shortage Does It for You
How AI, blockchain, multi-sourcing, and smarter policy can cut costs, eliminate fragility, and keep patients supplied Generic drugs fill 89%
Fix Your Generic Drug Supply Chain Before a Shortage Does It for You Read Post »
The Patent Cliff Playbook: Pharmaceutical IP Valuation, Generic Entry Timing, and Biosimilar Strategy
A technical deep dive for pharma IP teams, R&D leads, and institutional investors Master Key Takeaways A drug’s market monopoly
